AI-generated summary
The authors studied photobiomodulation at 660 and 830 nm in mice with an experimental model of complex regional pain syndrome type I, with and without nicotine exposure. They report that both wavelengths reduced mechanical and thermal hyperalgesia and paw edema, with 660 nm showing better results for hyperalgesia, and that the harmful effects of nicotine were softened by treatment. As an experimental mouse study, these findings may not apply directly to people.
- Participants
- 64
- Who or what was studied
- Swiss mice (experimental animal model of complex regional pain syndrome type I)
- Wavelengths
- 660, 830 nm
- Limits stated in the abstract
- The study was conducted in mice using an induced ischemia/reperfusion model, so the results may not translate to human CRPS.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.org.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm, 660 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.